MiR-145 suppresses thyroid cancer growth and metastasis and targets AKT3

Endocrine-Related Cancer

Volumn 21, Issue 4, 2014, Pages 517-531

  Boufraqech, Myriem ^a   Zhang, Lisa ^a   Jain, Meenu ^a   Patel, Dhaval ^a   Ellis, Ryan ^a   Xiong, Yin ^a   He, Mei ^a   Nilubol, Naris ^a   Merino, Maria J ^b   Kebebew, Electron ^a  

^a Medical Oncology Branch   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

AKT3; Biomarker; Metastasis; MiR 145; Thyroid cancer

Indexed keywords

AKT3 PROTEIN; CASPASE; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; HERMES ANTIGEN; MICRORNA 145; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN; PROTEIN KINASE B; PROTEIN P21; PROTEIN TYROSINE PHOSPHATASE; THYROGLOBULIN; TRANSCRIPTION FACTOR PAX8; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; AKT3 PROTEIN, HUMAN; MICRORNA; MIRN145 MICRORNA, HUMAN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CASE REPORT; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DEDIFFERENTIATION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL EVALUATION; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISTANT METASTASIS; DOWN REGULATION; ENZYME INHIBITION; EXOSOME; FINE NEEDLE ASPIRATION BIOPSY; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PERIPHERAL CIRCULATION; PREDICTIVE VALUE; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TARGETING; RNA EXTRACTION; SIGNAL TRANSDUCTION; THYROID CANCER; THYROID CANCER CELL LINE; THYROID FOLLICLE CELL; THYROID METASTASIS; THYROID NODULE; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CELL CYCLE CHECKPOINT; GENETICS; LUNG TUMOR; METABOLISM; NUDE MOUSE; PATHOLOGY; SECONDARY; THYROID TUMOR; TUMOR CELL LINE; TUMOR INVASION; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; LUNG NEOPLASMS; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; THYROID NEOPLASMS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84905973616     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-14-0077     Document Type: Article

References (47)

1. Akao Y, Nakagawa Y & Naoe T 2006 MicroRNAs 143 and 145 are possible common onco-microRNAs in human cancers. Oncology Reports 16 845-850. (doi:10.3892/or.16.4.845)
2. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzo M et al. 2006 Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Molecular Cancer 5 29. (doi:10.1186/1476-4598-5-29)
3. Brase JC, Wuttig D, Kuner R & Sultmann H 2010 Serum microRNAs as non-invasive biomarkers for cancer. Molecular Cancer 9 306. (doi:10.1186/1476- 4598-9-306)
4. Burrows N, Resch J, Cowen RL, von Wasielewski R, Hoang-Vu C, West CM, Williams KJ & Brabant G 2010 Expression of hypoxia-inducible factor 1α in thyroid carcinomas. Endocrine-Related Cancer 17 61-72. (doi:10.1677/ERC-08- 0251)
5. Ceppi P & Peter ME 2014 MicroRNAs regulate both epithelial-to- mesenchymal transition and cancer stem cells. Oncogene 33 269-278. (doi:10.1038/onc.2013.55)
6. Chandramohan V, Jeay S, Pianetti S & Sonenshein GE 2004 Reciprocal control of Forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27Kip1 levels. Journal of Immunology 172 5522-5527. (doi:10.4049/jimmunol.172.9.5522)
7. de la Chapelle A & Jazdzewski K 2011 MicroRNAs in thyroid cancer. Journal of Clinical Endocrinology and Metabolism 96 3326-3336. (doi:10.1210/jc.2011-1004)
8. Cheng GZ, Park S, Shu S, He L, Kong W, Zhang W, Yuan Z, Wang LH & Cheng JQ 2008 Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Current Cancer Drug Targets 8 2-6. (doi:10.2174/156800908783497104)
9. Cibas ES & Ali SZ 2009 The Bethesda system for reporting thyroid cytopathology. Thyroid 19 1159-1165. (doi:10.1089/thy.2009.0274)
10. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y & Greenberg ME 1997 Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 231-241. (doi:10.1016/S0092-8674(00)80405-5)
11. De Craene B & Berx G 2013 Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews. Cancer 13 97-110. (doi:10.1038/nrc3447)
12. Fan L, Wu Q, Xing X, Wei Y & Shao Z 2012 MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochimica et Biophysica Sinica 44 407-414. (doi:10.1093/abbs/gms019)
13. Fang J, Ding M, Yang L, Liu LZ & Jiang BH 2007 PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cellular Signalling 19 2487-2497. (doi:10.1016/j.cellsig.2007.07.025)
14. Gan B, Lim C, Chu G, Hua S, Ding Z, Collins M, Hu J, Jiang S, Fletcher-Sananikone E, Zhuang L et al. 2010 FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell 18 472-484. (doi:10.1016/j.ccr.2010.10.019)
15. Huang S, Guo W, Tang Y, Ren D, Zou X & Peng X 2012 miR-143 and miR-145 inhibit stem cell characteristics of PC-3 prostate cancer cells. Oncology Reports 28 1831-1837. (doi:10.3892/or.2012.2015)
16. Islam A, Shen X, Hiroi T, Moss J, Vaughan M & Levine SJ 2007 The brefeldin A-inhibited guanine nucleotide-exchange protein, BIG2, regulates the constitutive release of TNFR1 exosome-like vesicles. Journal of Biological Chemistry 282 9591-9599. (doi:10.1074/jbc.M607122200)
17. Johnston RJ Jr, Chang S, Etchberger JF, Ortiz CO & Hobert O 2005 MicroRNAs acting in a double-negative feedback loop to control a neuronal cell fate decision. PNAS 102 12449-12454. (doi:10.1073/pnas.0505530102)
18. Kitano M, Rahbari R, Patterson EE, Steinberg SM, Prasad NB, Wang Y, Zeiger MA & Kebebew E 2012 Evaluation of candidate diagnostic microRNAs in thyroid fine-needle aspiration biopsy samples. Thyroid 22 285-291. (doi:10.1089/thy.2011.0313)
19. Lacroix L, Michiels S, Mian C, Arturi F, Caillou B, Filetti S, Schlumberger M & Bidart JM 2006 HEX, PAX-8 and TTF-1 gene expression in human thyroid tissues: a comparative analysis with other genes involved in iodide metabolism. Clinical Endocrinology 64 398-404. (doi:10.1111/j.1365-2265. 2006.02477.x)
20. Li Y, Zhang H & Chen Y 2011 MicroRNA-mediated positive feedback loop and optimized bistable switch in a cancer network involving miR-17-92. PLoS ONE 6 e26302. (doi:10.1371/journal.pone.0026302)
21. Luo X, Stock C, Burwinkel B & Brenner H 2013 Identification and evaluation of plasma microRNAs for early detection of colorectal cancer. PLoS ONE 8 e62880. (doi:10.1371/journal.pone.0062880)
22. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E & Los M 2007 Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resistance Updates 10 13-29. (doi:10.1016/j.drup.2007.01.003)
23. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A et al. 2008 Circulating microRNAs as stable blood-based markers for cancer detection. PNAS 105 10513-10518. (doi:10.1073/pnas.0804549105)
24. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, Poon TC, Ng SS & Sung JJ 2009 Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 58 1375-1381. (doi:10.1136/gut.2008.167817)
25. Onoue T, Uchida D, Begum NM, Tomizuka Y, Yoshida H & Sato M 2006 Epithelial-mesenchymal transition induced by the stromal cell-derived factor-1/CXCR4 system in oral squamous cell carcinoma cells. International Journal of Oncology 29 1133-1138. (doi:10.3892/ijo.29.5.1133)
26. Pallante P, Visone R, Ferracin M, Ferraro A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M, Negrini M et al. 2006 MicroRNA deregulation in human thyroid papillary carcinomas. Endocrine-Related Cancer 13 497-508. (doi:10.1677/erc.1.01209)
27. Pallante P, Battista S, Pierantoni GM & Fusco A 2014 Deregulation of microRNA expression in thyroid neoplasias. Nature Reviews. Endocrinology 10 88-101. (doi:10.1038/nrendo.2013.223)
28. Patel KN & Shaha AR 2006 Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13 119-128.
29. Ren D, Wang M, Guo W, Zhao X, Tu X, Huang S, Zou X & Peng X 2013 Wild-type p53 suppresses the epithelial-mesenchymal transition and stemness in PC-3 prostate cancer cells by modulating miR145. International Journal of Oncology 42 1473-1481. (doi:10.3892/ijo.2013.1825)
30. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K & Mo YY 2009 p53 represses c-Myc through induction of the tumor suppressor miR-145. PNAS 106 3207-3212. (doi:10.1073/pnas.0808042106)
31. Schlumberger M 2007 Papillary and follicular thyroid carcinoma. Annales d'Endocrinologie 68 120-128. (doi:10.1016/j.ando.2007.04.004)
32. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, Garcia YK, Min YD, Grossman RF, Siperstein AE et al. 1997 Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. Journal of Clinical Endocrinology and Metabolism 82 3741-3747. (doi:10.1210/jcem.82.11.4340)
33. Solomides CC, Evans BJ, Navenot JM, Vadigepalli R, Peiper SC & Wang ZX 2012 MicroRNA profiling in lung cancer reveals new molecular markers for diagnosis. Acta Cytologica 56 645-654. (doi:10.1159/000343473)
34. Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, Jung A, Kirchner T & Brabletz T 2006 A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 131 830-840. (doi:10.1053/j.gastro.2006.06.016)
35. Theoharis C, Roman S & Sosa JA 2012 The molecular diagnosis and management of thyroid neoplasms. Current Opinion in Oncology 24 35-41. (doi:10.1097/CCO.0b013e32834dcfca)
36. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P, Brugger B & Simons M 2008 Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 319 1244-1247. (doi:10.1126/science.1153124)
37. Tuttle RM, Fleisher M, Francis GL & Robbins RJ 2002 Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation. Journal of Clinical Endocrinology and Metabolism 87 1737-1742. (doi:10.1210/jcem.87.4.8388)
38. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ & Lotvall JO 2007 Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nature Cell Biology 9 654-659. (doi:10.1038/ncb1596)
39. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G et al. 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11 1569-1579.
40. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M et al. 2006 A microRNA expression signature of human solid tumors defines cancer gene targets. PNAS 103 2257-2261. (doi:10.1073/pnas.0510565103)
41. Wang Z, Zhang X, Yang Z, Du H, Wu Z, Gong J, Yan J & Zheng Q 2012 MiR-145 regulates PAK4 via the MAPK pathway and exhibits an antitumor effect in human colon cells. Biochemical and Biophysical Research Communications 427 444-449. (doi:10.1016/j.bbrc.2012.06.123)
42. Wright PA, Lemoine NR, Goretzki PE, Wyllie FS, Bond J, Hughes C, Roher HD, Williams ED & Wynford-Thomas D 1991 Mutation of the p53 gene in a differentiated human thyroid carcinoma cell line, but not in primary thyroid tumours. Oncogene 6 1693-1697. (Pubitemid 21924276)
43. Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D, Lai L & Jiang BH 2012 MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Research 40 761-774. (doi:10.1093/nar/gkr730)
44. Yang J, Dai C & Liu Y 2005 A novel mechanism by which hepatocyte growth factor blocks tubular epithelial to mesenchymal transition. Journal of the American Society of Nephrology 16 68-78. (doi:10.1681/ASN.2003090795)
45. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S & Itakura M 1992 Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Research 52 5061-5064.
46. Zhang J, Sun Q, Zhang Z, Ge S, Han ZG & Chen WT 2013 Loss of microRNA-143/145 disturbs cellular growth and apoptosis of human epithelial cancers by impairing the MDM2-p53 feedback loop. Oncogene 32 61-69. (doi:10.1038/onc.2012.28)
47. Zhong WB, Liang YC, Wang CY, Chang TC & Lee WS 2005 Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocrine-Related Cancer 12 615-629. (doi:10.1677/erc.1.01012)